Vinay joined the firm in January 2021. He contributes to the investment team’s fundamental research process as a life sciences/biotech specialist given his extensive clinical research experience. Vinay previously worked as an associate with McKinsey & Co where he served clients in the Pharmaceutical/Medical Product (PMP) sector and Healthcare Systems and Services (HSS) division. Prior to management consulting, he was part of the COVID-19 pandemic response effort at Duke University Medical Center serving in both a clinical and strategic capacity. He was also the co-founder and Chief Technology Officer of Enumeral Biomedical where he sought to develop a cell-based immune profiling and diagnostics platform. He received both his medical (M.D.) and graduate (Ph.D.) degrees at Duke University School Of Medicine and his undergraduate education (BS in Biology) at the Massachusetts Institute of Technology (MIT). His doctoral thesis focused on understanding the way cells recognize and respond to DNA damage. While at MIT, he helped found an immune diagnostics and drug discovery company and spent time at the National Institutes of Health (NIAID) conducting research in the fields of HIV immunology and autoimmunity. Vinay has over 10 years of clinical research experience in the fields of molecular/genomic diagnostics, targeted oncology, allergy/immunology, rheumatology and critical care.